SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) today announced that clinical investigators from leading hematology research centers around the world will present data from recent and ongoing clinical trials of multiple Celgene products at the 12th International Myeloma Workshop from February 26 – March 1, 2009 in Washington, D.C. A total of 70 abstracts, including 14 oral presentations will report important findings in all areas of myeloma treatment, with an emphasis on survival benefits being delivered by new, innovative therapies and the importance of long-term disease control.
